慢性心力衰竭患者血浆CTRP5水平变化被引量：5

下载PDF

导出

摘要目的观察慢性心力衰竭(CHF)患者血浆补体C1q肿瘤坏死因子相关蛋白5(CTRP5)水平变化,并探讨其临床意义。方法将67例CHF患者作为CHF组,其中NYHA分级Ⅱ级22例、Ⅲ级20例、Ⅳ级25例,同时选取20例正常人作为对照组。采用ELISA法测定两组血浆CTRP5、N末端前脑钠肽(NT-pro-BNP)水平,比较CHF组与对照组、不同NYHA分级CHF患者血浆CTRP5水平,并分析CHF患者血浆CTRP5水平与NT-pro-BNP的相关性。结果 CHF组、对照组血浆CTRP5水平分别为(72.32±22.42)、(36.07±16.85)ng/m L,NT-pro-BNP水平分别为(953.58±132.53)、(59.69±19.64)ng/L,两组相比P均<0.01。CHF组中NYHA分级Ⅱ、Ⅲ、Ⅳ级患者血浆CTRP5水平分别为(51.18±14.13)、(74.07±20.05)、(89.53±12.98)ng/m L,两两相比P均<0.05。CHF组血浆CTRP5水平与NT-pro-BNP水平呈正相关(r=0.845,P<0.01)。结论 CHF患者血浆CTRP5水平升高;CTRP5水平变化有助于判断CHF患者的心功能分级。

作者韩思梁刘素云张瑞宁

机构地区河北医科大学第二附属医院

出处《山东医药》 CAS 北大核心 2017年第22期47-48,共2页 Shandong Medical Journal

关键词慢性心力衰竭 C1q肿瘤坏死因子相关蛋白5 N末端前脑钠肽

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献1

1李明春,陆林,陈秋静,张瑞岩,张奇,沈卫峰.血清CTRP9水平与冠心病的关系[J].国际心血管病杂志,2013,40(5):323-325. 被引量：10

二级参考文献13

1Wong GW, Wang J, Hug C, et al. A family of Acrp30/ adiponectin structural and functional paralogs[J]. Proc Natl Acad Sci U S A,2004,101(28) :10302- 10307.
2Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to CIq, produced exclusively in adipocytes [J]. J Biol Chem,1995,270(45) :26746-26749.
3Sehfiffler A, Buechler C. CTRP family: linking immunity to metabolism[J]. Trends Endocrinol Metab, 2012, 23 (4): 194-204.
4Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, et al. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin[J]. FASEB J, 2009, 23(1): 241-258.
5Kambara T, Ohashi K, Shibata R, et al. CTRP9 protects against myocardial injury following isehemia-reperfusion through AMPK-dependent mechanism [J]. J Biol Chem, 2012, 287(23) : 18965-18973.
6Su H, Yuan Y, Wang XM,et al. Inhibition of CTRP 9, a novel and cardiac-abundantly expressed cell survival molecule by TNF-alpha-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice [J]. Basic Res Cardiol, 2013, 108(1): 315.
7Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons; endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine [J]. Circulation, 2007 ,116(7):e148-e304.
8Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee [J]. Circulation, 2008,117 (2) :296-329.
9Fruebis, J, Tsao, "IS, Javorschi, S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss inmiee[J]. Proc Natl Acad Sci U S A, 2001, 98 (4): 2005-2010.
10Berg AH, Combs TP, Du X, et ah The adipocyte-secreted protein Acrp30 enhances hepatic insulin action[J]. Nat Med, 2001,7(8) :947-953.